At the HL7 Genomics Conference, a FHIR Genomics developer unveiled the Consortium for Agile Genomics to promote implementation of the nascent standard.
Genome Canada and its partners recently funded two new initiatives with C$255 that will back precision medicine, genomics, and technology development.
The creator of the Genome Aggregation Database sees an ever-expanding GnomAD database as a centerpiece to improving the diagnosis of rare diseases.
Such an atlas could enable investigators to understand how genetic variants impact disease risk, define drug toxicities, improve therapies, and advance regenerative medicine.
The company is providing several of its Parsortix instruments to the CANCER-ID consortium as part of an effort to establish liquid biopsy in routine clinical practice.
Backed by €15 million in EU funding, the Ubiquitous Pharmacogenomics Consortium seeks to implement preemptive testing at seven healthcare systems by 2020.
The firm said that the consortium will expand a database that provides insights for clinical partners and shows unusual patterns of drug resistance.
The institutes are also collaborating with 30 research groups in academia and industry, and have tapped Sage Bionetworks to handle data analysis.
Research centers in six countries will work on metabolome-related global health challenges including autism, cancer, diabetes, dementia, and obesity.
NantHealth, CHOP, and their collaborators intend to release genomic, transcriptomic, and proteomic data from 1,600 patients in the next six months
US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.
A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.
The New York Times writes about the appearance of mosaicism in healthy people.
In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.